Navigation Links
Researchers discover molecular basis of a form of muscular dystrophy
Date:4/30/2008

A team of French and German researchers report in the May 2008 print issue of The FASEB Journal (http://www.fasebj.org) that people with limb-girdle muscular dystrophy are missing a protein called c-FLIP, which the body uses to prevent the loss of muscle tissue. By targeting the cellular and molecular mechanisms responsible for creating this protein, scientists could develop new drugs to stop muscle wasting from limb-girdle muscular dystrophy and other conditions.

Unfortunately, rare diseases like limb-girdle muscular dystrophy dont get the attention or funding they deserve, said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. I hope that the breakthrough described in this studythe discovery of what regulates a protein that determines which muscle tissue stays and goes in our bodieswill lead to a range of new drugs for this form of muscular dystrophy and many others.

To identify c-FLIP as a culprit in limb-girdle muscular dystrophy, the researchers used tissue from human biopsies to analyze the molecular pathways involved at each step of the disorders progression. The researchers found that the c-FLIP protein, which is responsible for blocking the death of muscle cells, is not produced as it should in people with limb-girdle muscular dystrophy, and that the creation of the c-FLIP protein is controlled by another protein called calpain-3. According to the authors, this finding may have implications for other types of muscular dystrophy and other situations that cause the death of muscle fibers, such as long-term immobilization, denervation, aging, or cachexia.

Limb-girdle muscular dystrophy is a rare and devastating condition that robs people of movements that the rest of us take for granted, Weissmann added. Fortunately, this study should provide researchers with a much-needed target for developing drugs to treat at least one of these conditions.

According to the U.S. Muscular Dystrophy Association, limb-girdle muscular dystrophy is a group of disorders affecting voluntary muscles around the hips and shoulders, and it is caused by mutations in at least 15 genes responsible for making proteins needed for normal muscle function. As the disease progresses, people with limb-girdle muscular dystrophy may lose their ability to walk, get in and out of chairs, comb their hair, and feed themselves.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert  

Related biology news :

1. Sunflower debate ends in Mexico, researchers say
2. Carnegie Mellon researchers urge development of low carbon electricity
3. In computer models and observations, researchers see potential for significant red tide season
4. Montana State researchers study spread of lake trout in Glacier National Park
5. Medical College researchers find dinosaur clues in fat
6. Researchers discover gene for branchio-oculo-facial syndrome
7. Researchers reveal structure of protein that repairs damage to cancer cells
8. Purdue researchers propose way to incorporate deforestation into climate change treaty
9. Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme
10. FISH-BOL: NOAA researchers help build a global reference library of DNA barcodes
11. Researchers uncover details about how dietary restriction slows down aging
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers discover molecular basis of a form of muscular dystrophy
(Date:1/13/2017)... N.Y. , Jan. 13, 2017 ... technology solutions for the homecare industry, including Electronic ... homecare industry expert, Justin Jugs, as Senior Vice ... more than 15 years of homecare experience to ... in developing strategic plans to align Sandata,s suite ...
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... (PRWEB) , ... January 20, 2017 , ... ... consulting and resource to the healthcare industry ( http://www.gandlscientific.com ), has announced the ... expanding team of clinical and scientific consultants and contractors. This is the latest ...
(Date:1/21/2017)... N.J. , Jan. 20, 2017 ... "Company"), a company that provides clinically useful molecular ... it has entered into a securities purchase agreement ... of 855,000 shares of common stock in a ... the Company has agreed to sell to the ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo Bioworks, ... Gen9, a pioneer in the synthesis and assembly ... expertise in assembling pathway-length synthetic DNA into Ginkgo,s ... capacity in the construction of new organism designs ... "Gen9 was founded to significantly increase ...
Breaking Biology Technology: